Summary & Overview

CPT 0226U: Tru–Immune Neutralizing Antibody Assay

CPT code 0226U designates a Proprietary Laboratory Analyses (PLA) test for the Tru–ImmuneTM assay from Ethos Laboratories, GenScript® USA, which assesses the neutralizing capacity of antibodies against SARS–CoV–2 in a blood sample. As a PLA code, 0226U applies only to this specific manufacturer's test and is used by laboratories and payers to identify the unique service.

This national-level overview addresses coverage and billing considerations for major payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical purpose of the assay, typical sites where the service is performed, and the implications of a PLA designation for coding clarity and payer identification.

The publication summarizes benchmarks and policy-relevant points: how PLA coding distinguishes manufacturer-specific proprietary tests, the role of neutralizing antibody measurement in post-infection and post-vaccination assessment, and the operational coding elements laboratories must report. It also flags areas where payer policy language or national reimbursement guidance commonly affects adoption and claims handling. Data not available in the input are noted where applicable, and readers will gain a concise reference for billing, coding, and clinical context related to CPT code 0226U.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0226UCPTProprietary Laboratory Analysesneutralizing antibody assaySARS-CoV-2laboratory diagnosticsPLA codereference lab

Billing Code Overview

CPT code 0226U is a Proprietary Laboratory Analyses (PLA) code reported for the Tru–ImmuneTM test from Ethos Laboratories by GenScript® USA. The test measures the current neutralizing capacity of antibodies against the SARS–CoV–2 virus in a blood sample and is specific to this single manufacturer's assay.

Service type: Proprietary laboratory diagnostic test (neutralizing antibody assay)

Typical site of service: Clinical laboratory or reference laboratory

Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult or pediatric patient presenting for assessment of immune protection against SARS–CoV–2, either after recent vaccination, prior infection, or exposure, or when evaluating immune status before immunosuppressive therapy. The clinician orders the Tru–Immune™ neutralizing antibody test performed by Ethos Laboratories (GenScript® USA). A phlebotomy appointment is scheduled at an outpatient laboratory, hospital outpatient phlebotomy unit, or ambulatory clinic. A blood specimen (serum or plasma per lab instructions) is collected, labeled with patient identifiers, and shipped to Ethos Laboratories under required temperature and handling conditions.

Laboratory processing includes receipt, accessioning, and performing the proprietary neutralization assay that quantifies antibody-mediated inhibition of SARS–CoV–2 spike protein–ACE2 interaction. Results are reported as a numeric neutralizing antibody level and interpretive comment about current neutralizing capacity. The result is routed to the ordering provider via the electronic health record or secure report; clinicians use the result for counseling on infection risk, need for booster vaccination, or managing immunosuppressed patients. Typical sites of service are outpatient laboratory, hospital outpatient, ambulatory clinic, or mobile phlebotomy services. Common clinical indications include post-vaccination immune assessment, evaluation after confirmed or suspected SARS–CoV–2 infection, assessment in immunocompromised patients, and pre-exposure risk evaluation for high-risk procedures or travel.

Coding Specifications

Modifier	Description	When to Use

00

Taxonomy Code	Specialty	Notes
183P00000X	Pathology and Laboratory Medicine	Clinical laboratory directors and specialists overseeing test validation and reporting.
207Q00000X	Infectious Disease	Ordering clinicians who evaluate SARS–CoV–2 immunity in complex patients.
207L00000X	Allergy & Immunology	Specialists assessing immune response in immunodeficiency or immunomodulatory therapy.
207R00000X	Internal Medicine	Primary care and hospitalists ordering tests for post-vaccination or post-infection assessment.
208000000X	Family Medicine	Outpatient clinicians ordering immune status testing for counseling and preventive care.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z23`	Encounter for immunization	May be used when assessing neutralizing antibody levels after vaccination to determine response.
`U07.1`	COVID-19, virus identified	Relevant for assessing neutralizing antibodies after confirmed SARS–CoV–2 infection.
`Z79.899`	Other long term (current) drug therapy	Relevant when evaluating patients on chronic immunosuppressive medications that may impair vaccine response.
`D84.9`	Immunodeficiency disorder, unspecified	Used when assessing antibody-mediated immunity in patients with primary or secondary immunodeficiency.
`Z71.89`	Other specified counseling	May be used when counseling patients about immune status based on neutralization assay results.
`R68.89`	Other general symptoms and signs	Used when non-specific symptoms prompt assessment of immune status post-exposure or post-infection.
`Z00.6`	Encounter for examination for normal comparison and control in clinical research program	Used when neutralizing antibody testing is performed in the context of clinical research or surveillance.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0260U`	Measurement of SARS–CoV–2 neutralizing antibodies, semi-quantitative or quantitative; specific proprietary method	Alternative PLA neutralization assay; may be ordered by the same clinician or used by different labs as a comparable test.
`86413`	Severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) antigen or antibody detection by immunoassay, qualitative or semiquantitative; multiple types	Common antibody immunoassay often ordered alongside neutralizing antibody testing for broader serostatus assessment.
`86769`	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2)	Commonly billed for SARS–CoV–2 antibody detection to document prior infection or vaccine response in conjunction with neutralization testing.
`36415`	Collection of venous blood by venipuncture	Phlebotomy CPT for blood collection required before performing the proprietary laboratory neutralization assay.
`99000`	Handling and/or conveyance of specimen for transfer from physician's office to a laboratory (transportation)	Billing for specimen transport when separate billing is required by payer; supports chain-of-custody and timely delivery for testing.